These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27840695)

  • 1. Optimized p53 immunohistochemistry is an accurate predictor of
    Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
    J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
    [No Abstract]   [Full Text] [Related]  

  • 2. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance.
    Dundr P; Hájková N; Kendall Bártů M; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I
    Pathology; 2023 Oct; 55(6):785-791. PubMed ID: 37500307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
    Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
    Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for
    Li J; Wang J; Su D; Nie X; Liu Y; Teng L; Pang J; Wu H; Liang Z
    Gastroenterol Res Pract; 2021; 2021():2510195. PubMed ID: 34956360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
    Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
    Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel Somatic
    Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.
    Biatta CM; Paudice M; Greppi M; Parrella V; Parodi A; De Luca G; Cerruti GM; Mammoliti S; Caroti C; Menichini P; Fronza G; Pesce S; Marcenaro E; Vellone VG
    Front Immunol; 2023; 14():1221605. PubMed ID: 37680633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of
    Boyarskikh UA; Gulyaeva LF; Avdalyan AM; Kechin AA; Khrapov EA; Lazareva DG; Kushlinskii NE; Melkonyan A; Arakelyan A; Filipenko ML
    Front Oncol; 2020; 10():1103. PubMed ID: 32766142
    [No Abstract]   [Full Text] [Related]  

  • 14. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
    Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
    Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.
    Armbruster H; Schotte T; Götting I; Overkamp M; Granai M; Volmer LL; Bahlinger V; Matovina S; Koch A; Dannehl D; Engler T; Hartkopf AD; Brucker SY; Bonzheim I; Fend F; Staebler A; Montes-Mojarro I
    Virchows Arch; 2024 Oct; 485(4):631-642. PubMed ID: 39191994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing.
    Lee H; Cho YA; Kim DG; Son JY; Cho EY
    Anticancer Res; 2024 Sep; 44(9):3983-3994. PubMed ID: 39197898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
    Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma.
    Orachum P; Temtanakitpaisan A; Kleebkaow P; Chumworathayi B; Luanratanakorn S; Aue-Angkul A; Itarat Y
    Obstet Gynecol Sci; 2022 Sep; 65(5):459-467. PubMed ID: 35903943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.
    Kuhn E; Kurman RJ; Vang R; Sehdev AS; Han G; Soslow R; Wang TL; Shih IeM
    J Pathol; 2012 Feb; 226(3):421-6. PubMed ID: 21990067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.